Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA)

被引：0
|
作者：
Santini, Valeria [1 ]
Fenaux, Pierre [2 ]
Mufti, Ghularn J. [3 ]
Hellstrom-Lindberg, Eva [4 ]
Silverman, Lewis B. [5 ]
List, Alan [6 ]
Gore, Steven D. [7 ]
Seymour, John F. [8 ]
Backstrom, Jay [9 ]
McKenzie, David [9 ]
Beach, C. L. [9 ]
机构：
[1] Azienda Osped Careggi, Florence, Italy
[2] Univ Paris 13, Hop Avicenne, AP HP, Hematol Clin, Bobigny, France
[3] Kings Coll London, Dept Haematol Med, London, England
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Peter MacCallum Canc Inst, Dept Haematol, Melbourne, Vic, Australia
[9] Celgene, Overland Pk, KS USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：583 / 584
页数：2
相关论文
共 50 条
  • [41] Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
    Diez-Campelo, Maria
    Lorenzo, Jose I.
    Itzykson, Raphael
    Rojas, Silvia M.
    Berthon, Celine
    Luno, Elisa
    Beyne-Rauzy, Odile
    Perez-Oteyza, Jaime
    Vey, Norbert
    Bargay, Joan
    Park, Sophie
    Cedena, Teresa
    Bordessoule, Dominique
    Munoz, Juan A.
    Gyan, Emmanuel
    Such, Esperanza
    Visanica, Sorin
    Lopez-Cadenas, Felix
    de Botton, Stephane
    Hernandez-Rivas, Jesus M.
    Ame, Shanti
    Stamatoullas, Aspasia
    Delaunay, Jacques
    Salanoubat, Celia
    Isnard, Francoise
    Guieze, Romain
    Perez Guallar, Joan
    Badiella, Llorenc
    Sanz, Guillermo
    Canizo, Consuelo
    Fenaux, Pierre
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (03) : 350 - 359
  • [42] Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Itzykson, Raphael
    Thepot, Sylvain
    Quesnel, Bruno
    Dreyfus, Francois
    Beyne-Rauzy, Odile
    Turlure, Pascal
    Vey, Norbert
    Recher, Christian
    Dartigeas, Caroline
    Legros, Laurence
    Delaunay, Jacques
    Salanoubat, Celia
    Visanica, Sorin
    Stamatoullas, Aspasia
    Isnard, Francoise
    Marfaing-Koka, Anne
    de Botton, Stephane
    Chelghoum, Youcef
    Taksin, Anne-Laure
    Plantier, Isabelle
    Ame, Shanti
    Boehrer, Simone
    Gardin, Claude
    Beach, C. L.
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2011, 117 (02) : 403 - 411
  • [43] Management of non-haematological adverse events in MDS patients treated with lenalidomide
    Giagounidis, A.
    Cazzola, M.
    Fenaux, P.
    Mufti, G.
    Muus, P.
    Platzbecker, U.
    Sanz, G.
    Cripe, L.
    Von Lilienfeld-Toal, M.
    Wells, R.
    LEUKEMIA RESEARCH, 2007, 31 : S121 - S122
  • [44] Practical recommendations on the management of haematological adverse events in MDS patients treated with lenalidomide
    Giagounidis, A.
    Cazzola, M.
    Fenaux, P.
    Mufti, G.
    Muus, P.
    Platzbecker, U.
    Sanz, G.
    Cripe, L.
    Von Lilienfeld-Toal, M.
    Wells, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 82 - 82
  • [45] The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Barnard, John
    Al Ali, Najla H.
    Zimmerman, Cassie
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Jabbour, Elias
    Kantarjian, Hagop
    Zell, Katrina
    Wang, Quiqing
    Gore, Steven D.
    Nazha, Aziz
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2014, 124 (21)
  • [46] A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Bennett, John M.
    Silverman, Lewis R.
    Seymour, John F.
    Hellstrom-Lindberg, Eva
    Swern, Arlene S.
    Beach, Charles. L.
    List, Alan. F.
    HAEMATOLOGICA, 2013, 98 (07) : 1067 - 1072
  • [47] Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
    Jill A. Bell
    Aaron Galaznik
    Marlo Blazer
    Huai-Che Shih
    Eileen Farrelly
    Augustina Ogbonnaya
    Michael Eaddy
    Robert J. Fram
    Douglas V. Faller
    PharmacoEconomics - Open, 2019, 3 : 237 - 245
  • [48] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 199 - 199
  • [49] Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
    Bell, Jill A.
    Galaznik, Aaron
    Blazer, Mario
    Shih, Huai-Che
    Farrelly, Eileen
    Ogbonnaya, Augustina
    Eaddy, Michael
    Fram, Robert J.
    Faller, Douglas, V
    PHARMACOECONOMICS-OPEN, 2019, 3 (02) : 237 - 245
  • [50] Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
    Chen, James Yuhtyng
    Johnson, Lisa
    McKenna, Kelly Marie
    Choi, Timothy S.
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan M.
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris H. M.
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345